Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Long-term Debt

Borrowings due after more than one year.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $343.97M, compared with $0 a year earlier.

Context

  • Long-term debt amounted to 72.8% of total assets at the end of Q1 FY2026, up 72.8 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$343.97M-0.3% QoQ
Last fiscal yearDec 2025
$344.96M+4.0% YoY
Year agoMar 2025
$0— since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+4.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
344.96M USD
Year-over-year change
+4.0%
4-year CAGR
+104.1%

Long-term Debt vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's Mar 2026 long-term debt of $343.97M is the 2nd highest of the 11 companies compared; the peer median is $15.65M.
  • Long-term debt amounts to 72.8% of total assets for SNDX, versus a peer median of 5.5%.
SNDX Competitors Peer median
Long-term Debt for SNDX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ZYMEZymeworks Inc.Sep 2026$597.15M ——50.8%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$343.97M ——72.8%
NUVBNuvation Bio Inc.Jun 2026$244.53M +420.6%—32.8%
RCUSArcus Biosciences, Inc.Jun 2026$101M +4.1%—10.9%
REPLReplimune Group, Inc.Dec 2025$47.63M +3.6%—14.3%
MGNXMacroGenics, Inc.Mar 2026$31.3M ——14.4%
XNCRXencor, Inc.Jun 2026$0 ——0.0%
NRIXNurix Therapeutics, Inc.Aug 2026$0 ——0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
CTMXCytomX Therapeutics, Inc.Mar 2026$0 ——0.0%
ALXOALX Oncology Holdings Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding SNDX) $15.65M+3.9%—5.5%

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents221.97M74.36M295.39M154.08M134.93M
Short-term Investments224.87M410.04M282.19M428.83M278.76M
Net Receivables429K4.06M1.23M13.87M70.29M
Inventory000366K32.75M
Other Current Assets265K117K63K(2.02M)1.22M
Total Current Assets448.4M489.79M580.88M603.06M528.08M
Property, Plant & Equipment (Net)1.26M1.06M1.5M2.02M1.52M
Goodwill00000
Intangible Assets00000
Long-term Investments05.47M29.83M119.52M0
Tax Assets00000
Other Non-current Assets0922K680K217K102K
Total Non-current Assets1.26M7.45M32M121.76M1.63M
Total Assets449.66M497.24M612.88M724.82M529.71M
Account Payables5.67M4.35M9.96M11.63M16.58M
Short-term Debt00012.12M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities6.23M6.55M35.92M15.75M103.06M
Total Current Liabilities20.68M29.07M58.1M103.55M120.12M
Long-term Debt19.9M00331.57M344.96M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000(1.05M)
Total Non-current Liabilities20.61M722K588K333.14M344.96M
Total Liabilities41.29M29.79M58.68M436.69M465.08M
Common Stock6K7K8K9K9K
Retained Earnings(543.7M)(693.04M)(902.4M)(1.22B)(1.51B)
Accumulated OCI45K(806K)218K163K452K
Other Stockholders Equity00000
Minority Interest00000
Total Equity408.37M467.45M554.2M288.12M64.63M
Total Debt20.97M1.16M1.64M345.74M346.48M
Net Debt(201M)(73.2M)(293.76M)191.66M211.55M

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.